Reneuron Share Discussion Threads

[volsung] 27/1/2023 11:32

Biotech and oilers lead to the poorhouse

[riskyinvestor] 27/1/2023 11:19

£7m Market Cap for a Biotech is cheap with £10m in cash

[riskyinvestor] 27/1/2023 11:15

So they have plenty of cash into 2024

[arab3] 27/1/2023 11:10

true to your name lol good luck

[riskyinvestor] 27/1/2023 11:08

If it is good for Miles then it is good for me

[fred177] 23/1/2023 16:24

He spends 10k wow what a punt

[tomboyb] 23/1/2023 15:31

rns -

dir buys shares-

[the stigologist] 19/1/2023 09:05

Directors Deals for Reneuron (RENE)

Announced Action Notifier Price Currency Amount

02-Sep-22 Buy Iain G Ross 27.70 GBX 60,000
02-Sep-22 Buy Iain G Ross 26.00 GBX 30,000
02-Sep-22 Buy Iain G Ross 25.85 GBX 10,000
14-Jul-22 Buy Catherine Isted 31.90 GBX 50,000
13-Jul-22 Buy Barbara Staehelin 30.32 GBX 127,000

Expect to see some averaging down given buys within last 6 months in 25-31p range

[the stigologist] 19/1/2023 08:34

Placing potentially delayed until H2 2023 ?

[blackhorse23] 13/1/2023 10:32

Placing coming any time !

[lovewinshatelosses] 04/1/2023 18:12

Well, seems a fair call, given the lack of deals during her tenure. Buck stops there, and all that. The key question is whether Iain, or Catherine's replacement, can achieve what she was unable to. High, high, risk proposition, but a rapid multibagger if they can in the coming months, IMO. Very short runway, which is why this is trading at such a lowly valuation. I think they clearly have some IP of value, but whether or not the value can be unlocked, in time for existing shareholders anyway, is the big question. Similar to 4D, and we all know the likely final outcome for holders there (of which I am one myself). You buy these types of outfits with your eyes wide open. Or, if you are boring and sensible, you stick to the big caps. And probably make more money over the longer term anyway :)

[digger2779] 04/1/2023 15:17

Maybe she wasn't all that good at her job? Ian Ross finally got Silence Therapeutics right but it took years.

[lovewinshatelosses] 03/1/2023 08:30

Am surprised the price did not open at least 30% down on that news. Not adding to my punt holding here, but watching with interest to see if Iain can achieve what Catherine was unable to. At least she bought a respectable amount of shares when in seat, unlike so many AIM BOD's. A shame she could not deliver, but I wish her well for this reason.

[terminator101] 03/1/2023 07:19

Oh dear, seems that Catherine wasn’t a keeper huh. Back to normal then with the useless pedestrian scientists stumbling around in the dark like they are running a 6th form science project.

———;——̵2;——R12;——

profit718 Dec '22 - 21:41 - 8431 of 8432
0 1 0
hxxps://youtu.be/q_9O-Lr-jCM



CEO was at #AstraZeneca making the Covid vaccine 😲

Now she can repeat her success on @ReNeuronPLC then £10M Mcap could become £70M Mcap

[terminator101] 30/12/2022 08:19

How are the longs doing in this pedestrian lifestyle pish? Come on lads you seem to have given up.

[profit7] 18/12/2022 21:41

hxxps://youtu.be/q_9O-Lr-jCM



CEO was at #AstraZeneca making the Covid vaccine 😲

Now she can repeat her success on @ReNeuronPLC then £10M Mcap could become £70M Mcap

[profit7] 18/12/2022 13:56

770% to level with the valuation
#RENE #RENUERON currently 10.5p [...]
We continue to value ReNeuron at £44.2m or 77p per share. [...]

[profit7] 18/12/2022 13:50

RENE
RENEURON

£6M MKT CAP AND TALK OF A BIG PHARMA DEAL!!


Sp ALL TIME LOW

[profit7] 18/12/2022 13:49

£6M MKT CAP AND TALK OF A BIG PHARMA DEAL!!


Sp ALL TIME LOW

[profit7] 18/12/2022 13:44

RENE was at 30p,
Seller took this to 10p

Oversold on The charts, looks primed to go on a run.
Santa run coming ON RENE

[profit7] 18/12/2022 13:28

Commercial deal coming!!

as per rns

ReNeuron's CustomExTM platform is the only platform that offers this ability to customise the exosome cell type for a partners' need and the payload / target cell of their choice, while offering a scalable and repeatable manufacturing process due to its patented conditional immortalisation technology. This technology was enabled through the Company's earlier work in producing GMP stem cells approved by the FDA and MHRA for the clinic from which the Company's exosomes are now produced.

[profit7] 18/12/2022 13:26

Way undervalued RENE

Mcap £6M

Cash £10M that c77% discount Share price from cash level.